1. Colorectal Cancer: Current “Standard” Uses for Molecular Testing

2. Disclosures

3. Improvement in Outcomes: Metastatic Colon Cancer

4. CALGB / SWOG 80405: Bevacizumab vs Cetuximab in First-Line KRAS ex 2 WT mCRC

5. CALGB / SWOG 80405: Bevacizumab vs Cetuximab in First-Line KRAS ex 2 WT mCRC

6. CALGB / SWOG 80405: Bevacizumab vs Cetuximab in First-Line KRAS ex 2 WT mCRC

7. Metastatic Colorectal Cancer

8. FIRE-3: Overall Survival in All RAS WT

9. Metastatic Colorectal Cancer

10. A Proven Biomarker: Pan-RAS Testing for Anti-EGFR Therapy

12. KRAS Mutations

13. KRAS and Front Line anti-EGFR

14. Pan-RAS Mutations and anti-EGFR

15. Highly Promising Biomarkers: Testing for MSI and HER-2 amplification

16. Immunotherapy for MMR-Deficient Cancers

17. HER-2 Targeted Therapy for GE AdenoCa

18. HER-2 Targeted Therapy for CRC

19. Summary - “Standard of Care” Testing for CRC

20. Thank You